Clinical Trials Logo
  1. Home
  2. Cancer of Unknown Primary Site
  3. NCT04131621

Nivolumab/Ipilimumab in Second Line CUP-syndrome — CheCUP  

Cancer of Unknown Primary Site Clinical Trial

Official title:
A Phase II, Open-label, Non-randomized, Multi-center Study Evaluating the Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Cancer of Unknown Primary Site Who Are Relapsed After or Refractory to Platinum-based Chemotherapy

Clinical Trial Summary

To compare the efficacy of nivolumab plus ipilimumab in subjects with high vs. Intermediate/low TMB poor-prognosis CUP (non-specific subset) who are relapsed or refractory to platinum-based first-line chemotherapy.

To evaluate the efficacy of nivolumab plus ipilimumab in subjects with poor-prognosis CUP (non-specific subset) who are relapsed or refractory to platinum-based first-line chemotherapy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04131621
Study type Interventional
Source University Hospital Heidelberg
Contact Alwin Kraemer
Phone 0049622142
Email a.kraemer@dkfz.de
Status Recruiting
Phase Phase 2
Start date December 12, 2019
Completion date December 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT03278600 - Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary Phase 3
Recruiting NCT04504604 - TCF-001 TRACK (Target Rare Cancer Knowledge) Study N/A
Completed NCT03053466 - APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors Phase 1
Active, not recruiting NCT04750109 - Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers
Recruiting NCT04952103 - Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Recruiting NCT04969835 - A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Phase 1
Active, not recruiting NCT03498521 - A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Phase 2
Completed NCT01845337 - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Phase 2
Recruiting NCT05263700 - FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary N/A
Active, not recruiting NCT03752333 - Trial of Pembrolizumab in Cancer of Unknown Primary Phase 2
Completed NCT05841966 - Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary N/A
Recruiting NCT04459273 - Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers Phase 1
Active, not recruiting NCT05024968 - Sintilimab in Cancer of Unknown Primary Phase 2